Blood Res.  2023 Sep;58(3):161-163. 10.5045/br.2023.2023057.

Atypical posterior reversible encephalopathy syndrome secondary to dasatinib

• Nayak AR
• Yadav D
• Naranje P
• Dass J
• Kumar P
• Aggarwal M

• KMID: 2546322
• DOI: http://doi.org/10.5045/br.2023.2023057

Figure

• 

  Fig. 1 T2/FLAIR MRI of brain reveals hyperintense signals in the left parietal and bilateral occipital lobes.

Reference

1. Fugate JE, Rabinstein AA. 2015; Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 14:914–25. DOI: 10.1016/S1474-4422(15)00111-8. PMID: 26184985.

2. McCormack PL, Keam SJ. 2011; Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 71:1771–95. DOI: 10.2165/11207580-000000000-00000. PMID: 21902298.

3. Fischer M, Schmutzhard E. 2017; Posterior reversible encephalopathy syndrome. J Neurol. 264:1608–16. DOI: 10.1007/s00415-016-8377-8. PMID: 28054130. PMCID: PMC5533845.

4. Rabinstein AA, Mandrekar J, Merrell R, Kozak OS, Durosaro O, Fugate JE. 2012; Blood pressure fluctuations in posterior reversible encephalopathy syndrome. J Stroke Cerebrovasc Dis. 21:254–8. DOI: 10.1016/j.jstrokecerebrovasdis.2011.03.011. PMID: 21536456.

5. Bartynski WS, Boardman JF. 2007; Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 28:1320–7. DOI: 10.3174/ajnr.A0549. PMID: 17698535. PMCID: PMC7977645.

6. Hobson EV, Craven I, Blank SC. 2012; Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int. 32:590–4. DOI: 10.3747/pdi.2012.00152. PMID: 23212858. PMCID: PMC3524908.

7. Nekoukar Z, Moghimi M, Salehifar E. 2021; A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. Blood Res. 56:229–42. DOI: 10.5045/br.2021.2021117. PMID: 34776414. PMCID: PMC8721448.

8. Guignabert C, Phan C, Seferian A, et al. 2016; Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 126:3207–18. DOI: 10.1172/JCI86249. PMID: 27482885. PMCID: PMC5004960.